<DOC>
	<DOCNO>NCT01613690</DOCNO>
	<brief_summary>The purpose study see body process get rid NVA237 people impair kidney function compare people whose kidney function normal .</brief_summary>
	<brief_title>Comparing Pharmacokinetics , Safety Tolerability NVA237 Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male female subject age 18 70 year age inclusive . Female subject childbearing potential must use two acceptable method contraception , ( e.g. , intrauterine device plus condom , spermicidal gel plus condom , diaphragm plus condom , etc . ) , time screen duration study , study completion . Subjects must weigh least 50 kg participate study , must body mass index ( BMI ) within range 17 35 kg/m2 . Able communicate well investigator , understand comply requirement study . Understand sign write informed consent For renal insufficient subject Subjects must stable renal disease without evidence renal progressive disease ( purpose study stable renal disease define significant change 12 week ) . For health subject A serum creatinine within normal range eGFR &gt; 80 mL/min/1.73 m2 . For health subject Matched least one renal impaired subject undergo study age ( ±5 year ) , sex weight ( ±10 % BMI ) . Smokers ( use tobacco product previous 3 month ) . Smokers define subject report tobacco use and/or urine cotinine ≥ 500 ng/mL . If nonsmoking subject difficult recruit , smoker may allow participate study provide commit smoke 10 cigarettes/day day PKassessment For healthy subject , use prescription drug , herbal fitness/bodybuilding/athletic performanceenhancing supplement , within four ( 4 ) week prior initial dosing , and/or overthecounter ( OTC ) medication , dietary supplement ( vitamin include ) within two ( 2 ) week prior initial dose Recent ( within last three [ 3 ] year ) and/or recurrent history autonomic dysfunction ( e.g. , recurrent episode fainting ( unless relate water withdrawal dialysis ) , palpitation , etc ) . Recent ( within last three [ 3 ] year ) and/or recurrent history acute chronic bronchospastic disease ( include asthma chronic obstructive pulmonary disease , treat treat ) . History multiple recur allergy allergy investigational compound/compound class use study . Total WBC count fall outside range 300012,000/μL , platelet &lt; 100,000/μl screening . History immunodeficiency disease , include positive HIV ( ELISA Western blot ) test result . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Renal impairment</keyword>
	<keyword>NVA237</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>